• Logo
  • SBMUJournals

Non-Motor Symptoms of Parkinson’s Disease And Health-Related Quality Of Life: A Mini-Review

Ali Zafari, Parisa Amiri, Reza Taherian




Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, affecting seven million people globally. While the association of motor symptoms of PD with health-related quality of life (HRQoL) is extensively investigated, the effects of non-motor symptoms of PD, such as cognitive and behavioural symptoms, are recently highlighted. HRQoL reflects the physical, mental, and social aspects of health and is an essential subjective and reliable outcome measure of the disease. The current narrative review analyses recent literature on this topic focusing on studies in which behavioural symptoms of PD were considered as the main determinants of HRQoL.


Behavior; Psychiatric; Parkinson’s disease; Quality of Life


Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. The American journal of managed care. 2010;16:S87-93.

Pahwa R, Lyons KE. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. The American Journal of Managed Care. 2010;16:S94-9.

Johnson KE. Approach to the patient with Parkinson disease. Primary Care: Clinics in Office Practice. 2015;42(2):205-15.

Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ: British Medical Journal. 1998;316(7130):542.

Bullinger M. Measuring health related quality of life. Adamantiades-Behçet’s Disease. 2004:113-22.

Breslow L. A quantitative approach to the World Health Organization definition of health: physical, mental and social well-being. International journal of Epidemiology. 1972;1(4):347-55.

Krishnan S, Sarma G, Sarma S, Kishore A. Do nonmotor symptoms in Parkinson's disease differ from normal aging? Movement Disorders. 2011;26(11):2110-3.

Horstink M TE, Bonuccelli U, et al. Review of the therapeutic management of PD. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section: part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol. 2006;13:1170-85.

Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism & related disorders. 2011;17(1):1-9.

Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Movement Disorders. 2010;25(15):2493-500.

Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Supplement 4):S1-S136.

Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Archives of neurology. 1999;56(1):33-9.

Fauci AS BE, Kasper DL, et al. . Parkinson’s Disease and Other Extrapyramidal Movement Disorders. Harrison’s Principles of Internal Medicine 17th ed. New York, NY: McGraw Hill; 2008.

Witjas T, Kaphan E, Azulay J, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson’s disease Frequent and disabling. Neurology. 2002;59(3):408-13.

Maranis S, Tsouli S, Konitsiotis S. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(8):1795-807.

Varanese S, Birnbaum Z, Rossi R, Di Rocco A. Treatment of advanced Parkinson's disease. Parkinson’s Disease. 2011;2010.

Pahwa R, Factor S, Lyons K, Ondo W, Gronseth G, Bronte-Stewart H, et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-95.

Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62(1):37-40.

Lyons KE, Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. The American journal of managed care. 2011;17:S308-14.

M S. Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging. 2002;19:733-9.

Yeo L SR, Gundeti M, Barua JM, Masood J. . Urinary tract dysfunction in Parkinson’s disease: a review Int Urol Nephrol.

Wood LD, Neumiller JJ, Setter SM, Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. The American journal of geriatric pharmacotherapy. 2010;8(4):294-315.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE‐PD study. Annals of neurology. 2010;68(1):18-27.

Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Movement disorders. 2003;18(12):1459-63.

Witjas T, Kaphan E, Régis J, Jouve E, Chérif AA, Péragut JC, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Movement Disorders. 2007;22(12):1729-34.

Papatsoris A, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson’s disease. Urology. 2006;67(3):447-51.

A S. Quality of life and depression in Parkinson’s disease. J Neurol Sci. 2006;248((1-2)):151-7.

Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes O-B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism & related disorders. 2013;19(11):1027-32.

Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Movement Disorders. 2008;23(10):1428-34.

Leroi I, Ahearn DJ, Andrews M, McDonald KR, Byrne EJ, Burns A. Behavioural disorders, disability and quality of life in Parkinson's disease. Age and ageing. 2011;40(5):614-21.

Bach J-P, Riedel O, Klotsche J, Spottke A, Dodel R, Wittchen H-U. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. Journal of the neurological sciences. 2012;314(1):41-7.

Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism & related disorders. 2014;20(10):1071-5.

Fereshtehnejad S-M, Shafieesabet M, Farhadi F, Hadizadeh H, Rahmani A, Naderi N, et al. Heterogeneous determinants of quality of life in different phenotypes of Parkinson’s disease. PloS one. 2015;10(9):e0137081.

Fan J-Y, Chang B-L, Wu Y-R. Relationships among depression, anxiety, sleep, and quality of life in patients with Parkinson’s disease in Taiwan. Parkinson’s Disease. 2016;2016.

Therapies for depression in Parkinson’s disease. Cochrane Database of Syst Rev. [Internet]. 2003.

Clinicaltrials.gov. Study of Antidepressants in Parkinson’s Disease (SAD-PD). [Available from: http://clinicaltrials.gov/ct2/show/NCT00086190.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2010;9(6):573-80.

Badia X, Herdman M. The importance of health-related quality-of-life data in determining the value of drug therapy. Clinical therapeutics. 2001;23(1):168-75.

Troster AI LK, Straits-Troster KA. . Determinants of health-related quality of life changes in Parkinson’s disease. In: Martinez-Martin P, Koller WC, eds. Quality of Life in Parkinson’s Disease. . Barcelona: Masson S.A.1999. p. 55-77

Karlsen KH, Tandberg E, Årsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. Journal of Neurology, Neurosurgery & Psychiatry. 2000;69(5):584-9.

Jones JD, Butterfield LC, Song W, Lafo J, Mangal P, Okun MS, et al. Anxiety and depression are better correlates of Parkinson’s disease quality of life than apathy. The Journal of neuropsychiatry and clinical neurosciences. 2014;27(3):213-8.

Quelhas R CM. Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2009;21(4):413-9.

Hanna KK, Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson's disease. Parkinson’s Disease. 2011;2012.

Muslimović D, Post B, Speelman JD, Schmand B, de Haan RJ, Group CS. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;70(23):2241-7.

Alvarado-Bolaños A, Cervantes-Arriaga A, Rodríguez-Violante M, Llorens-Arenas R, Calderón-Fajardo H, Millán-Cepeda R, et al. Impact of neuropsychiatric symptoms on the quality of life of subjects with Parkinson’s disease. Journal of Parkinson's disease. 2015;5(3):541-8.

Dogan VB, Koksal A, Dirican A, Baybas S, Dirican A, Dogan GB. Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson’s disease. Neurological Sciences. 2015;36(12):2221-6.

Martinez‐Martin P, Rodriguez‐Blazquez C, Kurtis MM, Chaudhuri K. The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease. Movement Disorders. 2011;26(3):399-406.

DOI: http://dx.doi.org/10.22037/icnj.v4i3.17858


  • There are currently no refbacks.